Category: Press Releases

September 19, 2017 09:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035, an oral therapeutic in clinical development for the treatment of amyotrophic lateral sclerosis (ALS). The Company recently began a Phase 2 clinical study, the CENTAUR […]

Pre-clinical studies at Columbia University’s Motor Neuron Center Complement Amylyx Phase 2 Clinical Studies of Lead Therapeutic Compound New York, NY and Cambridge, MA (September 7, 2017) – Project ALS and Amylyx Pharmaceuticals today announced a collaboration to undertake pre-clinical studies with Amylyx’s oral compound AMX0035 to advance the understanding of the compound’s neurobiological effects. […]

Cambridge, MA, August 8, 2017 – Amylyx Pharmaceuticals, Inc., in collaboration with The ALS Association, ALS Finding a Cure®, and the Massachusetts General Hospital, today announced that the first patient was dosed in the CENTAUR study, a Phase II clinical trial assessing the efficacy and safety of AMX0035 for the treatment of amyotrophic lateral sclerosis […]

Amylyx Announces $5 Million Series A Financing to Support Phase II Clinical Trial of AMX0035 for Treatment of Amyotrophic Lateral Sclerosis Cambridge, Mass. (August 22, 2016) — Amylyx Pharmaceuticals Inc. announced today that it has completed a $5 million Series A financing to support its upcoming Phase II trial in patients with Amyotrophic Lateral Sclerosis […]

The ALS Association and ALS Finding a Cure Announce Joint Funding Support for Amylyx Clinical Trial of AMX0035 for the Treatment of ALS July 20, 2016 08:00 AM Eastern Standard Time Washington, D.C. and Cambridge, Mass. (July 20, 2016) — The ALS Association and Amylyx Pharmaceuticals based in Cambridge, Mass. are pleased to announce that […]

Amylyx Announces Election of Nobel Laureate Walter Gilbert, PhD, to Board of Directors | Business Wire January 19, 2016 10:00 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, a privately-held pharmaceutical company focused on disease-modifying treatments for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, today announced the election of Nobel Laureate and former Biogen […]

Amylyx Announces Support from the ALS Finding a Cure Foundation and the Cure Alzheimer’s Fund to Bring a New Treatment for Amyotrophic Lateral Sclerosis to Clinical Trials Novel therapeutic blocks nerve cell death and inflammation Clinical trials slated for 2016 Cambridge, MA, November 17, 2015 – Amylyx Pharmaceuticals today announced it has received $600,000 from […]